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Abstract
The lung alveoli slowly self-renew pneumocytes, but their facultative regeneration capacity
is rapidly efficient after an injury, so fibrosis infrequently occurs. We recently observed Kera-
tin 14 (KRT14) expression during diffuse alveolar damage (DAD), but not in controls. We
wonder if KRT14 may be a marker of pneumocyte transition from quiescence to regenera-
tion. Quantitative PCR and Western blot analyses highlighted the presence of KRT14
(mRNA and protein) only in human lung samples with DAD or interstitial lung disease (ILD).
In the exponentially growing cell lines A549 and H441, the mRNA and protein levels of
KRT14 peaked at day one after cell seeding and decreased at day two, opposite to what
observed for the proliferation marker E2F1. The inverse relation of KRT14 versus E2F1
expression holds true also for other proliferative markers, such as cyclin E1 and cyclin D1.
Of interest, we also found that E2F1 silencing caused cell cycle arrest and increased KRT14
expression, whilst E2F1 stimulation induced cell cycle progression and decreased KRT14.
KRT14 also increased in proliferative pneumocytes (HPAEpiC) just before transdifferentia-
tion. Overall, our results suggest that KRT14 is a viable biomarker of pneumocyte activation,
and repair/regeneration. The involvement of KRT14 in regenerative process may suggest a
novel pharmaceutical target to accelerate lung repair.
Introduction
The lung has a facultative regeneration ability: its reparative capacity is highly efficient, but the
differentiated cells re-enter the cell cycle only when needed [1]. Moreover, fibrosis after lung
injury may occur infrequently when this regenerative potential is upset or reduced [1]. In par-
ticular, ARDS (acute respiratory distress syndrome) with its pathological correlate DAD (diffuse
alveolar damage) may serve as a natural model for lung injury-repair, subsequent remodelling/
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disease, or regeneration and function recovery. In fact, while 40–60% of patients die, surviving
ARDS patients may experience pulmonary fibrosis or effective lung regeneration with complete
functional recovery after 1 year or less from the acute episode. The progenitor cells for lung
alveoli are the alveolar epithelial cells type 2 (pneumocytes type 2), while DN-p63+/KRT14
+ basal cells are progenitors for the airways [2]. After lung injury, type 2 pneumocytes prolifer-
ate and transdifferentiate into alveolar epithelial cells type 1 (pneumocytes type 1). Unfortu-
nately, this process is not usually reported by pathologists for the lack of effective biomarkers. In
a recent immunohistochemical study in human lung biopsy/autopsy samples, we showed that
lung alveoli express keratin 14 (KRT14) in DAD/ARDS [3]. Interestingly, this factor was never
found to be expressed in normal lung during progenitor cell quiescence. Therefore, the purpose
of the present study was to verify if KRT14 could be a distinct molecular marker of adult alveo-
lar cells (pneumocytes) transition from quiescence to regeneration. We assessed KRT14 mRNA
expression and protein levels not only in human fresh lung samples from patients/controls, but




Lung samples were obtained from 14 subjects (10 males), mostly were autopsies (9 cases) and
the remnants were surgical biopsies for diagnostic purpose.
The lung samples were distributed among three groups: 6 normal lungs, 4 ARDS, and 4
interstitial lung diseases (ILD). Tissue samples were immediately frozen after surgery and
stored at −80˚C until use. Either samples from biopsy and autopsy were obtained during rou-
tine clinical procedures performed according to the local standard guidelines and regulations
for diagnostic biopsy and autopsy. Written informed consent was obtained from all the biop-
sied patients or the patients’ next of kin in case of autopsy. This study was approved by the
institutional review board of the University of Trieste (ref. #48/2013).
Cells and cell culture
Human pulmonary alveolar epithelial cells (HPAEpiC) were purchased from ScienCell
Research Laboratories (Cat. No. 3200, Carlsbad, CA, USA). The HPAEpiC cells were isolated
from human lung tissue and characterized by ScienCell using immunostaining for specific
markers. According to the manufacturer’s specifications, they are only human alveolar type 2
epithelial cells (pneumocytes) [4, 5]. The human pulmonary alveolar epithelial cells were cul-
tured in the basal medium supplemented with growth factors according to the manufacturer’
instruction in T25 culture flasks coated with poly-L-lysine (2μg/cm2). The culture medium,
Alveolar Epithelial Cell Medium (ScienCell, #3201), was prepared by addition of 2% Fetal
Bovine Serum (FBS, ScienCell, #0010), 1% Epithelial Cell Growth supplement (EpiCGS 100x,
ScienCell, # 4152) and 1% of antibiotics (P/S 100x, 10000 units/mL. Penicillin—10000 μg/mL
Streptomycin, ScienCell, # 0503). The HPAEpiC phenotype was verified at our Lab by immu-
nocytochemistry with primary antibodies (DakoCytomation K0355, Denmark) and a chromo-
gen (diaminobenzidine 0.05%, Sigma Aldrich, Missouri USA) to detect ABCA3 and PhmTOR,
that are specific biomarkers of alveolar epithelial cells type 2.
The human lung adenocarcinoma cell lines H441 (ATCC-CCL-185, Manassas, VA, USA)
and A549 (ATCC-HTB-174, Manassas, VA, USA) were chosen as acceptable models of lung
surfactant-producing cells, were used as acceptable models of lung surfactant-producing cells,
representative of human lung alveolar epithelium [6]. H441 was cultured in RPMI medium,
A549 was cultured in Dulbecco’s modified Eagle’s high glucose medium DMEM (Euroclone,
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Celbio, Devon, UK). All media contained 10% fetal bovine serum (FBS), 2 mM L-glutamine,
100 U/ml penicillin and 100 μg/ml streptomycin (Euroclone, Celbio, Devon, UK). We evalu-
ated the mRNA levels of KRT14 in H441 and A549 cell lines maintained under optimal growth
conditions. To study the KRT14/cell proliferation ratio, we evaluated in parallel the mRNA
levels of E2F1, a known promoter of cell proliferation [7].
Real time PCR. RNA from lung samples: total RNA was extracted from lung samples
with Trifast reagent (Euroclone, Milan, Italy), according to manufacturer’s instruction.
Reverse transcription was performed with Moloney murine leukaemia virus (MMLV) Reverse
Transcriptase (Gibco-BRL, Life Technologies Inc., Frederick, MD, USA) and exameric ran-
dom primers, according to manufacturer’s protocol. In order to detect any genomic DNA con-
tamination, parallel reactions for each RNA sample were performed without MMLV.
Quantitative PCRs were performed on a CFX96 real-time PCR detection system with iQ SYBR







E2F1 (74 bp) F: CCAGGAAAAGGTGTGAAATC;
E2F1 (74 bp) R AAGCGCTTGGTGGTCAGATT
Cyclin E1 (112 bp) F: TGCCTGTACTGAGCTGGGCA;
Cyclin E1 (112 bp) R: GGCTGCAGAAGAGGGTGTTG;
CyclinD1 (70 bp) F: CCGTCCATGCGGAAGATC,
CyclinD1 (70 bp) R, 5’CCTCCTCCTCGCACTTCTGT.
The detailed qPCR conditions comprised 95˚C for 3 min, followed by 45 cycles of 95˚C for
15 sec and 60˚C for 30 sec. The relative expression levels were calculated according to 2^ΔCt
method, by using the equation ΔCt = Ct(target)−Ct(housekeeping) for Ct normalization. ΔCt
(KRT14-RPL13a) values of ARDS patients and controls were used to create box plots of the
real-time PCR measurements. The results represent the average and standard deviation of
three independent experiments, with two technical replicates.
RNA from cell lines: total RNA was extracted from cell lines, quantified and the quality
evaluated as previously described [8, 9]. Reverse transcription was performed using 1μg of
total RNA in the presence of random hexamers and MuLV reverse transcriptase (Applera Co.,
USA). The primers (MWG Biotech, GA, 300 nM) and the real-time amplification conditions
were as described [10, 11]. The relative amounts of each target mRNA were normalized by 28S
rRNA content. In the case of HPAEpiC, surfactant protein A1 (SFTPA1) and KRT14 were
quantitated by qPCR using the following program: 95˚C for 3 min, followed by 45 cycles of
95˚C for 15 sec and 60˚C for 30 sec.
siRNA and plasmid transfections. The sequence of the siRNA (Eurogentec S.A., Belgium)
directed against E2F1 mRNAs, has been previously reported [8]. The pool of three distinct siR-
NAs directed against KRT14 mRNA, was purchased by Dharmacon, (siGenome Smart Pool cat.
no. M010602-01). The day before transfection, H441 cells were seeded at a density of 3.8 × 103
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cells/cm2 in 6 well plates in the presence of 3 ml of 10% fetal calf serum-containing medium.
Transfections were performed using either the siRNAGL2 control siRNA (siGL2) or the specific
siRNAs (siE2F1/siKRT14). Optimal transfection conditions were obtained by using Lipofecta-
mine 2000 (1 mg/ml, Invitrogen) at a weight ratio siRNA-transfectant of 1:1. The mixture Lipo-
some–siRNA (200 and 100 nM for siE2F1 and siKRT14, respectively) was then administered
to the cells for 3 h at 37˚C in the presence of serum-free medium. Afterwards, transfection
medium was removed, cells were washed with 3 ml of PBS and then 4 ml of complete medium
were added to the cells. E2F1 and enhanced green fluorescence protein (EGFP) expression plas-
mids (pE2F1 and pEGFP, respectively), were previously described [8, 9]. Optimal transfection
conditions were set as reported [10]. Briefly, transfection mixture containing Lipofectamine
2000 (1 mg/ml, Invitrogen) and 2 μg of plasmidic DNA (weight ratio plasmid/transfectant of
1:2.5) was administered to 2.5 × 105 cells in six well plates for 4h at 37˚C in the presence of Opti-
mem. Thereafter, the transfection medium was removed and replaced with growth medium.
Target mRNA over-expression was observed at least for three days after transfection.
Western blot analysis. Protein extracts, separated by SDS-PAGE and transferred onto
nitrocellulose membranes (Whatman, Clifton, NJ, USA), were probed with antibodies against
KRT-14 (1:1000, ProteinTech, Chicago, IL). The following antibodies have been used: rabbit
anti-cyclin D1 (0.4 μg/ml) and rabbit anti-GAPDH (0.2 μg /ml) were purchased from Santa
Cruz Biotechnology (Santa Cruz, California, USA). The antibodies anti-KRT14, and mouse anti-
E2F1 (5 μg /ml) were purchased from BD Bioscience Pharmingen (San Jose, California, USA).
After incubation, the corresponding anti-rabbit or anti-mouse secondary HRP-conjugated anti-
body was used (Santa Cruz Biotechnology) and the blots developed using an enhanced chemilu-
minescent substrate (Supersignal West Pico, Pierce, Rockford, IL).
Statistical analysis
P values were calculated by the GraphPad InStat tools (GraphPad Software, Inc., La Jolla, CA,
USA) using the unpaired t-test with Bonferroni correction and the Mann-Whitney Test, as
appropriate. P values < 0.05 were considered statistically significant.
Results
Expression of KRT14 in normal and diseased human lung samples
The evaluation of KRT14 expression was performed on the lung samples from DAD, ILD, and
control subjects (see Table 1 for subject characteristics). Surfactant-B (SP-B) plays a critical
role in the functioning of healthy lungs and its impairment is commonly associated to acute
respiratory distress syndrome (ARDS) [12]. Initially, we tried to correlate the severity of ARDS
with the expression of SP-B, whose levels are known to be downregulated in the acute inflam-
matory lung diseases [12]. SP-B expression (tested by qPCR) was detected in 5 (out of 6) con-
trols, in 1 (out of 6) DAD and in none of ILD patients (Fig 1A). These findings further support
the hypothesis that a reduced SP-B expression is associated with severe lung dysfunction con-
ditions, such as ARDS [12]. In parallel, we performed quantification of KRT14 expression
both at mRNA and protein levels. Our patient population data show that in DAD (ARDS)
patients, the calculated ΔCt (CtKRT14 –CtRPL13a) values were low but positive and were ranging
between 2.76 and 4.45. On the contrary, the expression of KRT14 mRNA among the controls
was always undetectable in 4 normal lung samples. Finally, the ΔCt values were>10 (11.78
and 10.46) in two ILD samples, denoting negligible expression level compared to ARDS
patients (Fig 1B). Considering that the magnitude of the ΔCt values is inversely proportional
to the expression level, these results confirmed that KRT14 is actively expressed mainly in
DAD patients, even if some patient with ILD may also express it at low level. Consistent with
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these results, a Western blot analysis performed on the same lung specimens confirmed the
presence of immunoreactive material with MW compatible with that of KRT14 only in DAD
lung samples (Fig 1C).
KRT14 expression in proliferative human type II alveolar epithelial cells
Immunocytochemistry staining carried out with the human HPAEpiC, comprised of only
freshly cultured type 2 pneumocytes, showed that, at T = 0, these cells are ABCA3+ and Ph-
TOR+ cells (Fig 2A), and suggests that HPAEpic cells have a proliferative alveolar epithelial
cells type 2 phenotype, just before plating. Gene expression analysis at mRNA level monitored
by Real Time PCR showed a drop of KRT14 within 48 h, after thawing (Fig 2B). During the
same time slot, a decrease in the expression of the type 2 pneumocyte marker Surfactant Pro-
tein A1 (SFTPA1) was also monitored (Fig 2B). Even from a morphologic point of view, acti-
vated pneumocytes type 2 begin to change their shape before transdifferentiation from
hyperplastic phenotype at baseline (T = 0) to a non-proliferating phenotype just after 24–48
hours from plating. In conclusion, these results suggest that the expression of KRT14 progres-
sively decreases as transdifferentiation of pneumocytes type 2 towards type 1 starts.
Expression of KRT14 in cultured H441 and A549 human pulmonary
epithelial cells and its relationship with cell proliferation
To further explore the link between KRT14 expression with cell proliferation, we evaluated
KRT14/cell proliferation relation in two in-vitro models of human pneumocytes, namely H441
and A549 cell lines. To study the KRT14/cell growth relation, we evaluated KRT14 expression lev-
els and cell number; we also included the evaluation of the mRNA levels of E2F1, cyclin E1 and
cyclin D1, known promoters of cell proliferation interconnected by a positive feed-back loop [11].
Under the culturing conditions adopted, the growth of H441 and A549 cells was optimal as
highlighted by the steady increase of cell number and cell viability over time (Fig 3A and 3B).
In these conditions, KRT14 mRNA and protein levels were particularly elevated one day after
cell seeding, but significantly decreased two days after seeding (Fig 4A and 4C). In contrast,
the levels of the proliferation marker E2F1 (Fig 4B and 4C), cyclin E1 (Fig 4D) and cyclin D1
(Fig 4E) increased from day 1 to day 2, thus showing a trend inversely related to KRT14 levels
Table 1. List of controls and patients screened for Keratin 14 (KRT14) expression.
Subject Sex Age Lung histology RPL13a KRT14 ΔCt (KRT14- RPL13a)±SD
1 M 79 Normal + - nd
2 M 18 Normal + + 11.78±0.7
3 M 103 Normal + + 10.46±0.6
4 F 74 Normal + - nd
5 F 92 Normal + - nd
6 F 87 Normal + - nd
7 M 54 ARDS + + 3.69±0.1
8 M 86 ARDS + + 4.47±0.16
9 M 49 ARDS + + 2.76±0.22
10 F 86 ARDS + + 3.65±0.27
11 M 65 ILD + + 10.22±0.15
12 M 99 ILD + - nd
13 M 73 ILD + - nd
14 M 86 ILD + + 9.44±0.18
doi:10.1371/journal.pone.0172130.t001
Keratin14 marker of pneumocytes regeneration/repair
PLOS ONE | DOI:10.1371/journal.pone.0172130 February 15, 2017 5 / 15
Fig 1. Expression of KRT14 in ARDS, ILD and normal lungs. A) Assessment of Surfactant-B (SP-B)
expression at mRNA level. Box plots of the real-time PCR measurements asΔCt (SP—B-RLP13a) values of
ARDS patients (n = 4). ILD patients (n = 4) and Controls (n = 6). The box whisker plots visualize the minimum
(end of the bottom whisker), the first quartile (bottom border of the box), the median (line through the box), the
third quartile (top border of the box), and the maximum (end of the top whisker) of the distribution. DAD = diffuse
alveolar damage, ILD = interstitial lung disease. B) Assessment of KRT14 expression at mRNA level. Box plots
of the real-time PCR measurements asΔCt (KRT14-RPL13a) values of ARDS patients (n = 4), ILD patients
(n = 4) and Controls (n = 6).ΔCt values are shown in Table 1. The box whisker plots visualize the minimum (end
of the bottom whisker), the first quartile (bottom border of the box), the median (line through the box), the third
quartile (top border of the box), and the maximum (end of top whisker) of the distribution. C) Assessment of
KRT14 expression at protein level. The immunoreactive material with MW compatible with that of KRT14 protein
only in DAD patients. Upper panel: Western blot analysis. Lower panel: Ponceau red staining. The loading order
is indicated in between the two panels and the Subject numbers correspond to that shown in Table 1.
doi:10.1371/journal.pone.0172130.g001
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(Fig 4A and 4C). The observation that this inverse correlation between KRT14 and E2F1
occurs in two lung cell lines, suggests that the phenomenon is unlikely to represent a cell line-
dependent artifact. To confirm the inverse correlation between KRT14 and E2F1, we then
evaluated the effects of the siRNA-mediated depletion of E2F1 in H441 cells also considering
the other two proliferation markers, cyclin E1 and cyclin D1. This cell line was used because of
the higher transfection efficiency compared to the A549 line. Two days following siE2F1 trans-
fection (transfection rate 90 ± 2.7%, see S1A, S1B and S1E Fig), a significant reduction in cell
growth (Fig 5A) and in E2F1, cyclin E1 and cyclin D1 levels (Fig 5B and 5C) were observed,
compared to cells treated by the control siGL2 siRNA. In contrast, KRT14 levels were
increased (Fig 5B and 5C).
We then evaluated the effects of E2F1 over-expression on KRT14 mRNA levels. E2F1 over-
expression (transfection rate 94± 1,3%, see S1C, S1D and S1E Fig) resulted in a significant
growth stimulation three days after E2F1-encoding plasmid transfection, compared to cell
transfected by a control plasmid encoding the EGFP protein (Fig 5D). This time point revealed
an evident increase of E2F1 mRNA levels (Fig 5E) paralleled by an increase of the other two
proliferation markers cyclin E1 and cyclin D1, whose expression is related to E2F1. In contrast,
a remarkable decrease in KRT14 mRNA levels (Fig 5E) was observed. Together, these results
highlight the inverse relation between KRT14 and the E2F1-cyclin E1-cyclin D1 circuit.
Finally, to explore the functional role of KRT14 in H441 proliferation its expression was
downregulated by means of a specific pool of siRNAs (siKRT14). The data presented indicate
Fig 2. ABCA3/Ph-TOR staining in HPAEpiC and relative expression of KRT14/SFTPA. A) Immunocyto-
chemistry staining in human HPAEpiC, showing that, at T = 0, the cells are ABCA3 and Ph-TOR positive. B)
The mRNA expression of genes of interest, KRT14 and Surfactant protein A1 (SFTPA1) (type 2 pneumocyte
marker), was monitored just after thawing (T0), after 7 hours (T7), and after 48 hours (T48). The normalization
was carried out by using GAPDH and RPL13a housekeeping genes; data are reported as mean ± SD, n = 3,
*p<0.05 compared to T0.
doi:10.1371/journal.pone.0172130.g002
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that KRT14 silencing (Fig 6A) resulted in a modest reduction in H441 cell growth as evaluated
by cell counting (Fig 6B). Notably, KRT14 silencing also did not affect the mRNA level of the
E2F1-cyclin E1-cyclin D1 circuit (Fig 6A).
Discussion
We have previously showed that Keratin 14 (KRT14) is overexpressed in human lung alveoli
during diffuse alveolar damage (DAD), while normal lung do not [3]. DAD is a pulmonary
pathology showing either features of injured collapsed alveoli and lung tissue repair/regenera-
tion [13, 14]. The activation and proliferation of type 2 pneumocytes, a recognized progenitor
cell population in human adult lung [15], may reflect both alveolar damage and regeneration
[2, 16–18], but the process of KRT14 expression during pneumocytes proliferation and differ-
entiation was not yet clarified.
To further investigate the potential role of KRT14 expression during alveolar epithelial cell
proliferation and differentiation, we assessed KRT14 at transcriptional and protein levels in
quiescent, proliferating and differentiating pneumocytes. We studied human lung samples
with DAD and interstitial lung disease (ILD), and cultures of activated human alveolar epithe-
lial cells (HPAEpiC). Furthermore, we carried out in-vitro transfection experiments on H441
and A549 cell lines for arresting or inducing the cell proliferation by silencing/stimulating the
cell cycle regulatory protein-E2F1. We observed increased KRT14 mRNA and protein levels in
human lung biopsies of lung repair/regeneration, but not in quiescent normal lung specimens.
Of interest, it should be noted that also cultured pneumocytes showed increased KRT14
mRNA expression levels during activation of cell and before transdifferentiation (Fig 2). Fur-
ther work will be required to validate this observation at the protein expression level, because
it is well known that mRNA levels may not be proportional to protein levels, since the pro-
cesses of translation and protein degradation are at least as important as mRNA transcription
Fig 3. Kinetic of human pulmonary cell lines A549 and H441 growth. A) Cell count of A549 and H441
lines at day 0, 1, 2, and 3 in basal growth conditions. B) Cell viability of A549 and H441 lines at day 0, 1, 2, and
3 in basal growth conditions. All data are reported as mean ± SD.
doi:10.1371/journal.pone.0172130.g003
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and stability to steady-state protein abundance [19]. Nevertheless, we have detected the expres-
sion of KRT14 mRNA only in DAD lung samples and increased KRT14 protein levels were
found also in in-vitro experiments. In conclusion, all these experiments have allowed us to
expand our knowledge of KRT14 expression in lung injury. It is well known that KRT14 is a
key component of the intermediate cytoplasmic microfilaments which are essential for elonga-
tion, proliferation, and migration of epidermis progenitor epithelial cells in response to injury
[20, 21]. The dynamic assembly and disassembly of keratin-based cytoplasmic microfilaments
is needed to induce stemness in quiescent cells to foster tissue repair and regeneration [22, 23].
Keratins are also known to have a major function in providing stability to epithelial cells under
conditions of mechanical stress [24]. This is exemplified by cell frailty in human inherited ker-
atin disorders [25, 26], and in knockout mice expressing dominant-negative keratin subunits
Fig 4. Kinetic of KRT14, E2F1, cyclinE1 and cyclin D1 expression in human pulmonary cell lines A549
and H441. A) KRT14 mRNA levels in A549 and H441 lines at day 1 and 2 under basal growth conditions;
n = 6, *p<0,05 compared to day 1, data were normalized to the levels of 28S. B) E2F1 mRNA level in A549
and H441 lines at day 1 and 2 under basal growth conditions, n = 6, § p<0.05 compared to day 2, data were
normalized to the levels of 28S. C) Protein level of KRT14 and E2F1 in H441 assessed by Western blot at day
1 and 2 under basal growth conditions; GAPDH level was used for normalization. D) Cyclin E1 mRNA
expression level in H441 at day 1 and 2 under basal growth conditions, n = 5, + p<0.001 compared to day 2,
data were normalized to the levels of 28S. E) Cyclin D1 mRNA level in H441 at day 1 and 2 under basal
growth conditions, n = 5, # p<0.001 compared to day 2, data were normalized to the levels of 28S. All data are
reported as mean ± SD.
doi:10.1371/journal.pone.0172130.g004
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[27, 28]. In any epithelia the dynamic plasticity of keratin filaments allows cells to proliferate
during renewal growth and to migrate during wound healing [29]. KRT14 null mice show
Fig 5. Effects of E2F1 depletion/overexpression in the human pulmonary cell line H441. A) Cell count
at day 0,1,2, and 3 after E2F1 depletion by siRNA (siE2F1) compared with control siRNA (siGL2), n = 4,
+p<0,05 compared to siGL2. B) mRNA levels of KRT14, E2F1, cyclin E1 and cyclin D1 at day 2 after cell cycle
arrest caused by E2F1 depletion (siE2F1), n = 6, *p<0.05 compared to siGL2. C) Protein levels of KRT14 and
E2F1 in H441 assessed by Western blot at day 2 following E2F1 depletion by siE2F1; GAPDH level was used
for normalization. D) Cell count at day 0,1,2, and 3 after E2F1 overexpression, n = 3, ^p<0.05 compared to
pEGFP. E) mRNA expression levels of KRT14, E2F1, cyclin E1 and cyclin D1 at day 3 after cell cycle
progression induced by E2F1 overexpression (pE2F1) compared with an unrelated transfection vector
(pEGFP), n = 4, *p<0.05 compared to pEGFP. All data are reported as mean ± SD.
doi:10.1371/journal.pone.0172130.g005
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extensive blistering and die 2d after birth, indicating the functional importance of KRT14 in
maintaining mechanical integrity of the stratified epithelial cells [30, 31]. Moreover, KRT14
knockdown of epithelial cells leads to substantial reduction in cell proliferation [32]. Cellular
KRT14 expression in epithelia is higher when the pneumocytes change shape and move [22].
However, direct correlation with pneumocyte growth has never been observed before our
investigation. Our studies with pneumocyte derived cell lines indicate that KRT14 expression
is maximal in the initial phase of cell proliferation and then decreases (Figs 3 and 4A) with the
progression of cell growth. Remarkably, KRT14 expression is also high in the proliferating
HPAEpiC (pneumocytes type 2) and decreases after plating, a process that induces transdiffer-
entiation, as shown by the decrease in the expression of the pneumocyte type 2 marker
SFTPA1 (Fig 2B). The different experimental condition adopted to evaluate KRT14 expression
in pneumocyte cell lines and primary HPAEpiC depends on the very limited growth capacity
of this last cell type in-vitro. The fact that KRT14 silencing has a modest effect on H441 growth
(Fig 6) suggests that KRT14 may not have a pivotal role in the proliferation of the pneumo-
cyte-derived cell line we considered. However, we cannot exclude that this phenomenon may
depend on the kinetic of siKRT14 action. The siKRT14 used has the peak of mRNA silencing
activity at day two post transfection (Fig 6A and data not shown), which corresponds to the
starting point of the experiment. However, two days after plating (starting point of the
Fig 6. Effects of KRT14 depletion on KRT14, E2F1, cyclin E1 and cyclin D1 mRNA levels and cell
growth in human pulmonary cell line H441. A) KRT14 mRNA levels following siRNA-mediated depletion
(siKRT14), day two after siKRT14 transfection, n = 6, *p<0.05 compared to siGL2. E2F1, cyclin E1 and cyclin
D1 mRNA levels following cell treatment by siKRT14, day two after siKRT14 transfection, n = 6. B) Cell count
at day two after KRT14 depletion by siRNA (siKRT14) compared with control siRNA (siGL2). All data are
reported as mean ± SD.
doi:10.1371/journal.pone.0172130.g006
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experiment), KRT14 tends to drop (Fig 4A) in untreated H441. Thus, we cannot exclude that
siKRT14 mostly exerts its action when KRT14 is no longer so essential for H441 growth. Nota-
bly, also at an early time point (24hrs after siKRT14 transfection), no major effects on cell
growth were observed (data not shown). To fully unravelling the functional role of KRT14 in
pneumocytes, future experiments performed in primary pneumocytes are necessary.
Despite the uncertainty about the functional role of KRT14 in pneumocytes proliferation,
our data collectively point towards establishing the role of KRT14 as a marker of early prolifer-
ation in both cell types, strengthening our previous findings in-vivo [3], where we showed that
KRT14 immunoreactivity was mainly expressed in hyperplastic type 2 pneumocytes of lungs
having pathologic features of lung regeneration/repair [3]. Although features of wound-repair/
regeneration are common in DAD [33], it is not surprising that it can be also found in other
pulmonary diseases, like some ILD [34]. Our current findings confirm the expression of
KRT14 in most cases of ARDS-linked DAD (both at mRNA and protein levels), but also in
some patients with ILD having an ongoing repair process.
The expression of KRT14 during our in-vitro experiments inversely correlated with the pro-
liferative marker E2F1, cyclinE1 and cyclin D1 (Figs 4 and 5B–5E), similarly to our previous
observation done in human DAD specimens [3]. Moreover, in our previous work, we observed
that most KRT14+ pneumocytes were also Ki67-, another well-known proliferation marker.
Therefore, both alveolar epithelial cells during in-vitro growth and alveolar cells of human
DAD specimens show identical behavior, suggesting that our observations are consistent and
significant. Very recently, Eickelberg’group found similar results in distal airway epithelial
progenitor cells [35]. Both Eickelberg’s and our study may throw a new light on the key role of
KRT14 in the pathobiology of lung injury-linked diseases: this keratin is not expressed in air-
ways and alveoli during progenitor cells quiescence, but it is expressed during the initial phases
of repair/regeneration process. We did not explore the functional role of Keratin14 in experi-
mental models of fibrotic lung disease. Nevertheless, while several experimental models failed
to fit the real human disease [36], our results were obtained in human samples and in-vitro
human cell populations, so representing a convincing and intriguing proof of concept for fur-
ther experimental researches.
In conclusion, the results of our study suggest that KRT14 can be considered a viable bio-
marker of early lung regenerative/disease processes. Further studies on the progenitor proper-
ties of type 2 pneumocytes could lead to the discovery of novel therapeutic approaches for the
treatment of acute and chronic lung diseases.
Supporting information
S1 Fig. Transfection efficiency of FITC-labelled siRNA GL2 and of pEGFP. At the end of
transfection by FITC-labelled siGL2 (220 nM), FITC labelled cells were photographed (A-B) and
the amount (E) quantified by flow cytometry (data are expressed as mean ± SD, n = 4). 24 hours
after transfection by pEGFP, EGFP labelled cells were photographed (C-D) and the amount (E)
quantified by flow cytometry (data are expressed as mean ± SD, n = 4). Overexpression of E2F1
by pE2FP is shown by western blotting (F) in comparison to non transfected cells (NT).
(PDF)
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